These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34366212)

  • 1. Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
    Kartolo A; Kassouf W; Vera-Badillo FE
    Eur Urol; 2021 Dec; 80(6):679-681. PubMed ID: 34366212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
    Bellmunt J; Hussain M; Gschwend JE; Albers P; Oudard S; Castellano D; Daneshmand S; Nishiyama H; Majchrowicz M; Degaonkar V; Shi Y; Mariathasan S; Grivas P; Drakaki A; O'Donnell PH; Rosenberg JE; Geynisman DM; Petrylak DP; Hoffman-Censits J; Bedke J; Kalebasty AR; Zakharia Y; van der Heijden MS; Sternberg CN; Davarpanah NN; Powles T;
    Lancet Oncol; 2021 Apr; 22(4):525-537. PubMed ID: 33721560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
    Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
    Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle invasive bladder cancer: where is the field headed?
    Ghatalia P; Kaur J; Sonpavde G
    Expert Opin Biol Ther; 2023; 23(9):913-927. PubMed ID: 37477127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant therapy for muscle-invasive bladder cancer.
    Jain RK; Sonpavde G
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):603-614. PubMed ID: 32546025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
    Meeks JJ; Bellmunt J; Bochner BH; Clarke NW; Daneshmand S; Galsky MD; Hahn NM; Lerner SP; Mason M; Powles T; Sternberg CN; Sonpavde G
    Eur Urol; 2012 Sep; 62(3):523-33. PubMed ID: 22677572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
    de Ruiter BM; van Hattum JW; Lipman D; de Reijke TM; van Moorselaar RJA; van Gennep EJ; Maartje Piet AH; Donker M; van der Hulle T; Voortman J; Oddens JR; Hulshof MCCM; Bins AD
    Eur Urol; 2022 Nov; 82(5):518-526. PubMed ID: 35933242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small cell bladder carcinoma treated with nivolumab as adjuvant maintenance therapy.
    Kitamura K; Nonami T; Muto S; Horie S
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38160025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.
    Sonpavde G; Necchi A; Gupta S; Steinberg GD; Gschwend JE; Van Der Heijden MS; Garzon N; Ibrahim M; Raybold B; Liaw D; Rutstein M; Galsky MD
    Future Oncol; 2020 Jan; 16(2):4359-4368. PubMed ID: 31823654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
    Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
    Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy in muscle-invasive bladder cancer: ready for prime time?
    Pouessel D; Mongiat-Artus P; Culine S
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):288-94. PubMed ID: 23022113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
    Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
    Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Mertens LS; van der Heijden MS
    Lancet Oncol; 2024 Feb; 25(2):156-157. PubMed ID: 38142700
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
    J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.